Search Results

search
EnteroBiotix-Logo-R-Colour-WB-RGB.png
EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class Treatment for Irritable Bowel Syndrome (IBS)
March 18, 2025 04:00 ET | EnteroBiotix
EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class Treatment for Irritable Bowel Syndrome (IBS) EBX-102-02 demonstrated clinically meaningful...
cabrach logo.png
The Cabrach Trust challenges Canadian power giant over Scottish windfarm plan raised in Scottish Parliament
February 10, 2025 12:33 ET | The Cabrach Trust
Boralex's plans for a new wind farm in a remote Scottish Highland community have been raised in a Scottish Parliament debate.
CIP logo.png
Copenhagen Infrastructure Partners charges to the top of the UK battery stack
January 08, 2025 08:00 ET | Copenhagen Infrastructure Partners
LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Copenhagen Infrastructure Partners (CIP) has, through its flagship fund CI IV, taken Financial Investment Decision (FID) and issued Notice to Proceed (NTP)...
EnteroBiotix-Logo-R-Colour-WB-RGB.png
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome
November 18, 2024 08:00 ET | EnteroBiotix
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome 122 patients with moderate to severe irritable bowel syndrome (IBS) were recruited to EnteroBiotix’s Phase...
trogenix_RGB-80.jpg
Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy
November 18, 2024 08:00 ET | Trogenix
Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the...
EnteroBiotix-Logo-R-Colour-WB-RGB.png
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome
November 18, 2024 03:00 ET | EnteroBiotix
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome 122 patients with moderate to severe irritable bowel syndrome (IBS) were recruited to EnteroBiotix’s Phase...
trogenix_RGB-80.jpg
Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy
November 18, 2024 02:00 ET | Trogenix
Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the...
EnteroBiotix-Logo-R-Colour-WB-RGB.png
EnteroBiotix Announces Positive Ph1b Clinical Results of EBX-102 in Liver Cirrhosis
November 11, 2024 03:00 ET | EnteroBiotix
EBX-102 demonstrated proof-of-principle across multiple microbiome assessments, inflammatory biomarkers and clinical assessments, supporting its continued development as the first microbial therapy...
Edinburgh Park Arena Exterior - Front View
AEG Europe Secures Planning Permission for Edinburgh Park Arena
June 12, 2024 11:25 ET | AEG Europe
Edinburgh, UK, June 12, 2024 (GLOBE NEWSWIRE) -- AEG Europe, a global leader in live sport and entertainment, has received approved planning permission for a new state-of-the-art 8,500-capacity...
boyden-logo.png
Boyden Expands Presence in Energy Sector with Acquisition of FWB's Energy Practice in Scotland
March 19, 2024 03:15 ET | Boyden
Boyden has acquired FWB's Energy Practice in Scotland, UK, further expanding the global organization's presence in the energy sector.